Argos Therapeutics' Immunotherapy Platform Based On Recombinant Human Soluble CD83 Demonstrates Significant Promise For Solid Organ Transplantation
Links shared publicly online about this topic.
- 316total visits
Argos Therapeutics' Immunotherapy Platform Based On Recombinant Human Soluble CD83 Demonstrates Significant Promise For Solid Organ Transplantation
Argos Therapeutics announced that its immunotherapy platform based on recombinant human soluble CD83 demonstrated significant promise for renal and heart transplantation.Two studies were
View full resource at medicalnewstoday.com
Tags: Heart, Kidney Health, Urinary System, Organ Transplantation, Transplantation
Most Recently Shared on May 5, 2011 at 10:05 am By:
Argos Therapeutics' Immunotherapy Platform Based On Recombinant Human Soluble CD83 Demonstrates Significant Promise Fo... http://mnt.to/3VqV
Also Shared By:
Argos Therapeutics' Immunotherapy Platform Based on Recombinant Human Soluble CD83 Demonstrates Significant Promise For Solid Organ Transplantation - Drugs.com MedNews
drugs.com — “-Two Studies Presented at 2011 American Transplant Congress Show CD83 Is Associated With Kidney Allograft Tolerance and Modulates Antibody Mediated Rejection in” View full resource at drugs.com
Most Recently Shared on May 6, 2011 at 8:03 pm By:
Drugs and Devices OW OW Health
Argos Therapeutics' Immunotherapy Platform Based on Recombinant Human Soluble CD83 Demonstrates Significan... http://bit.ly/iSX0rH #drug
Advertisement
MNT Transplants News
@mnt_transplants
Argos Therapeutics' Immunotherapy Platform Based On Recombinant Human Soluble CD83 Demonstrates Significant Promise Fo... http://mnt.to/3VqV
1 year ago...